Minova

Minovia Therapeutics is a clinical-stage biotechnology company pioneering Mitochondrial Augmentation Therapy (MAT) for the treatment of rare mitochondrial diseases. The company's proprietary MAT platform involves enriching a patient's own hematopoietic stem and progenitor cells with healthy, functional mitochondria sourced from a donor to restore cellular energy production. Minovia is the first company to bring a mitochondrial cell therapy into clinical trials, with its lead program targeting Pearson Syndrome, a fatal multi-system genetic disorder. By addressing the root cause of mitochondrial dysfunction, the company aims to provide transformative treatments for a range of debilitating metabolic and genetic conditions.